| Patent Number |
Title Of Patent |
Date Issued |
| 7601740 |
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseas |
October 13, 2009 |
| Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this |
| 7576100 |
Muscarinic agonists |
August 18, 2009 |
| The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic recep |
| 7576078 |
Tetrahydroquinoline analogues as muscarinic agonists |
August 18, 2009 |
| The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic recep |
| 7550459 |
Tetrahydroquinoline analogues as muscarinic agonists |
June 23, 2009 |
| The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic recep |
| 7550454 |
Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatmen |
June 23, 2009 |
| Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuropsychiatric disorders. In some embodiments, the analogs are amino substituted |
| 7538222 |
N-substituted piperidine derivatives as serotonin receptor agents |
May 26, 2009 |
| Disclosed herein are compounds of Formula I, ##STR00001## or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof. Also disclosed are methods of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the mon |
| 7517871 |
Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatmen |
April 14, 2009 |
| Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some embodiments, the analogs are amino substituted |
| 7511053 |
Spiroazacyclic compounds as monoamine receptor modulators |
March 31, 2009 |
| The present invention relates to optionally substituted 1-oxa-3,8-diaza-spiro[4.5]decan-2-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease con |
| 7491715 |
Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatmen |
February 17, 2009 |
| Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuropsychiatric disorders. In some embodiments, the analogs are amino substituted |
| 7491503 |
Identification of ligands by selective amplification of cells transfected with receptors |
February 17, 2009 |
| The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions. The present invention also relates to a method of identifying compounds which act as inverse agonists of the |
| 7485651 |
Compounds with activity on muscarinic receptors |
February 3, 2009 |
| Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administe |
| 7476682 |
N-substituted piperidine derivatives as serotonin receptor agents |
January 13, 2009 |
| Disclosed herein are compounds of Formula I, ##STR00001## or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof. Also disclosed are methods of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the mon |
| 7452682 |
Identification of 5HT2A receptor ligands by selective amplification of cells transfected with re |
November 18, 2008 |
| The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions. The present invention also relates to a method of identifying compounds which act as inverse agonists of the |
| 7425420 |
Identification of ligands by selective amplification of cells transfected with a 5HT2A receptor |
September 16, 2008 |
| The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions. The present invention also relates to a method of identifying compounds which act as inverse agonists of the |
| 7402590 |
Spiroazacyclic compounds as monoamine receptor modulators |
July 22, 2008 |
| The present invention relates to optionally substituted 1-oxa-3,8-diaza-spiro[4.5]decan-2-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease con |
| 7351707 |
Spiroazacyclic compounds as monoamine receptor modulators |
April 1, 2008 |
| The present invention relates to optionally substituted 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease c |
| 7348140 |
Clinical indications for genotyping polymorphic variants of G-protein coupled receptors |
March 25, 2008 |
| The invention provides compositions and methods for screening individuals for the presence of G-protein coupled receptor (GPCR) variants. The compositions and methods are useful for determining clinical outcome of drug therapy or for tailoring drug therapy for the individual based upon |
| 7307075 |
Tetrahydroquinoline analogues as muscarinic agonists |
December 11, 2007 |
| The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic recep |
| 7300928 |
Benzimidazolidinone derivatives as muscarinic agents |
November 27, 2007 |
| Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M.sub.1 and/or M.sub.4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of tre |
| 7291611 |
Benzimidazolidinone derivatives as muscarinic agents |
November 6, 2007 |
| Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M.sub.1 and/or M.sub.4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of tre |
| 7288539 |
Spiroazacyclic compounds as monoamine receptor modulators |
October 30, 2007 |
| The present invention relates to optionally substituted 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease c |
| 7273857 |
Benzimidazolidinone derivatives as muscarinic agents |
September 25, 2007 |
| Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M.sub.1 and/or M.sub.4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of tre |
| 7268232 |
Androgen receptor modulators and method of treating disease using the same |
September 11, 2007 |
| Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating disease comprising administering a compound of For |
| 7238713 |
Muscarinic agonists |
July 3, 2007 |
| Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in ne |
| 7217719 |
Spiroazacyclic compounds as monoamine receptor modulators |
May 15, 2007 |
| The present invention relates to 1,3,8-triara-spiro[4.5]decan-2-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a m |
| 7087593 |
Benzimidazolidinone derivatives as muscarinic agents |
August 8, 2006 |
| Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M.sub.1 and/or M.sub.4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of tre |
| 6951958 |
Solid phase parallel synthesis of tertiary amines |
October 4, 2005 |
| Described is method for preparing tertiary amines comprising sequential, exhaustive alkylation of a hydroxylamine derivative and cleavage of the O--N bond using the following steps: a) reacting the hydroxylamine derivative with an alkylating agent or with a carbonyl compound to form a |
| 6951849 |
Benzimidazolidinone derivatives as muscarinic agents |
October 4, 2005 |
| Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M.sub.1 and/or M.sub.4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of tre |
| 6911452 |
Spiroazacyclic compounds as monoamine receptor modulators |
June 28, 2005 |
| The present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a |
| 6815458 |
Azacyclic compounds |
November 9, 2004 |
| Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment. |
| 6756393 |
Azacyclic compounds |
June 29, 2004 |
| Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment. |
| 6627645 |
Muscarinic agonists |
September 30, 2003 |
| Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in ne |
| 6528529 |
Compounds with activity on muscarinic receptors |
March 4, 2003 |
| Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administe |
| 5955281 |
Identification of ligands by selective amplification of cells transfected with receptors |
September 21, 1999 |
| The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions. |
